ライフサイエンスコーパス: T-cell immunity

1 studies unveil an essential role of Gpx4 for T cell immunity.

2 specific subsets of dendritic cells and CD8 T cell immunity.

3 ant peptide is virtually unable to stimulate T cell immunity.

4 re characterized by their ability to inhibit T cell immunity.

5 overlapping and yet distinct mucosal and DC/T cell immunity.

6 are considered to play little or no role in T cell immunity.

7 a broad spectrum of biological processes of T cell immunity.

8 formation of resident versus nonresident CD8 T cell immunity.

9 T cells into strategies designed to enhance T cell immunity.

10 esentation by pDCs in driving proatherogenic T cell immunity.

11 f NPs to distinct DC subsets led to enhanced T cell immunity.

12 which is critically dependent on Ag-specific T cell immunity.

13 monstrate the role of FA synthesis in CD8(+) T cell immunity.

14 tudies of the role of RAR isoforms in CD8(+) T cell immunity.

15 of the host to mount effective antiviral CD8 T cell immunity.

16 immune tolerance and tips the balance toward T cell immunity.

17 ly employed cytokines; and (4) activators of T cell immunity.

18 ammatory responses and in the suppression of T cell immunity.

19 heir JAK/STAT pathways play pivotal roles in T cell immunity.

20 nogenic state and promote the development of T cell immunity.

21 for the generation of virus-specific CD8(+) T cell immunity.

22 r tuberculosis, but other diseases requiring T cell immunity.

23 ion that influence memory formation and CD8+ T cell immunity.

24 d that P. aeruginosa induces MDSCs to escape T cell immunity.

25 erted their suppressive properties to induce T cell immunity.

26 mitations of human fetal and neonatal CD4(+) T cell immunity.

27 ated the mechanisms involved in LSEC-induced T cell immunity.

28 f novel VZV vaccines that specifically boost T cell immunity.

29 rime and boost for generating optimal CD8(+) T cell immunity.

30 nown about the mechanisms of LSECs to induce T cell immunity.

31 nce the magnitude, quality, and phenotype of T cell immunity.

32 (CD152) that acts as a negative regulator of T cell immunity.

33 ty and peripheral tolerance than in effector T cell immunity.

34 disease and the regulation of virus-specific T cell immunity.

35 be divergent in the costimulation of CD4(+) T cell immunity.

36 s central correlates of T cell tolerance and T cell immunity.

37 monella is via the development of protective T cell immunity.

38 eous chemical carcinogenesis, independent of T cell immunity.

39 1 (PD-1) in suppressing MiHA-specific CD8(+) T cell immunity.

40 ans are an essential component of long-lived T cell immunity.

41 lls but did not explain the defect in CD8(+) T cell immunity.

42 re critical for the generation of protective T cell immunity.

43 aneous and PD-L1-blockade-mediated antitumor T cell immunity.

44 M) subsets that likely compromise anti-tumor T cell immunity.

45 duction of IL-1beta, and defective antiviral T cell immunity.

46 or the generation of an optimal effector CD8 T cell immunity.

47 sepsis might facilitate the recovery of CD8 T cell immunity.

48 and inhibits formation of pathogen-specific T cell immunity.

49 ex class II expression, suggesting a role in T cell immunity.

50 tifiers to explore the long-term dynamics of T cell immunity.

51 e immunogenicity for inducing antibodies and T cell immunity.

52 e development of vaccines that evoke optimal T cell immunity.

53 and qualitatively altered YF-specific CD4(+) T cell immunity.

54 aling as a viable approach to augment CD8(+) T-cell immunity.

55 ory bowel disease-all with severely impaired T-cell immunity.

56 l inadequacy to evade HLA-A*02:01-restricted T-cell immunity.

57 2:01 molecule, and play an important role in T-cell immunity.

58 e immunoregulatory cytokine IL-10 suppresses T-cell immunity.

59 e of Th17 cells to preserve an effective HIV T-cell immunity.

60 e survival by inducing robust tumor-specific T-cell immunity.

61 cal strategy to harness endogenous antitumor T-cell immunity.

62 rism with superior long-term recovery of CD4 T-cell immunity.

63 nation immunotherapies that can fully engage T-cell immunity.

64 ibody responses, we found key differences in T-cell immunity.

65 vival is dependent on their ability to evade T-cell immunity.

66 ocols to establish lifelong antigen-specific T-cell immunity.

67 eraction is pivotal in all aspects of CD8(+) T-cell immunity.

68 ty independent of vaccine-specific B-cell or T-cell immunity.

69 tion to generate protective antiviral CD8(+) T-cell immunity.

70 pre-existing or treatment-induced antitumor T-cell immunity.

71 ficity and sensitivity in mediating adaptive T-cell immunity.

72 py is the induction of long-lasting systemic T-cell immunity.

73 re used to measure influenza-specific CD4(+) T-cell immunity.

74 ge about how acidic microenvironments affect T-cell immunity.

75 lied partly on induction of sustainable host T-cell immunity.

76 and "atypical" SCID show reduced, not absent T-cell immunity.

77 for sterols and oxysterols in macrophage and T-cell immunity.

78 igen-presenting cells to stimulate antitumor T-cell immunity.

79 was associated with enhanced virus-specific T-cell immunity.

80 DTP on innate proinflammatory responses and T-cell immunity.

81 ls, suggesting interference of carriage with T-cell immunity.

82 hanism involving the inhibition of antitumor T-cell immunity.

83 t facilitates the emergence of potent CD8(+) T-cell immunity able to durably suppress virus replicati

84 in single lymphoma nodes, mediated systemic T-cell immunity accompanied by regression of disseminate

85 n lung DCs abrogated the induction of CD8(+) T cell immunity after immunization with particulate anti

86 etween DC dysfunction and impairments in CD8 T cell immunity after sepsis by directly targeting Ag to

87 Quantifying CMV-specific T-cell immunity after HSCT can identify participants at

88 t critical for the generation of robust CD8+ T-cell immunity after s.s. with VACV.

89 edure to achieve reconstitution of antiviral T-cell immunity after SCT.

90 its potential for triggering protective CD8 T cell immunity against heterologous influenza virus cha

91 ispensable for establishing effective CD4(+) T cell immunity against malaria, because it not only inh

92 onal strategies for generating heterogeneous T-cell immunity against cancer, with the appropriate bal

93 t be possible to generate broadly protective T-cell immunity against commonly occurring virus escape

94 We previously described CD4(+) T-cell immunity against HBsAg and polymerase in chimpanz

95 ing cell motility are essential for adaptive T-cell immunity against infectious pathogens and cancers

96 th restoration of intrahepatic CD4+ and CD8+ T-cell immunity against multiple HCV proteins.

97 T-cell immunity against stem-cell antigen SOX2 and prese

98 During pregnancy women can develop B- and T-cell immunity against the inherited paternal antigens

99 c cells (LCs) are more potent stimulators of T-cell immunity against tumor and viral antigens in vitr

100 e acute stages of sepsis develop compromised T cell immunity and increased susceptibility to infectio

101 r inhibitory signals that suppress antiviral T cell immunity and likely contribute to persistent infe

102 s a critical immune regulator by suppressing T cell immunity and macrophage activation during inflamm

103 rs to be a crucial component of EBV-specific T cell immunity and more generally for the immune survei

104 he key discoveries in the area of flavivirus T cell immunity and postulate on how these findings can

105 expressing macrophages that inhibited CD8(+) T cell immunity and promoted CD4(+)Foxp3(+) Treg cell ex

106 inosinic-polycytidylic acid (poly IC) on CD8 T cell immunity and protection elicited by LAIVs.

107 e of various TLR ligands on SIV Gag-specific T cell immunity and protection following prime-boost imm

108 ponses results in significant alterations in T cell immunity and subsequent disease outcome upon reex

109 lized antigen-presenting cells that initiate T cell immunity and tolerance.

110 Induction of antiviral CD8(+) T-cell immunity and cytotoxicity was documented in WAS K

111 s recently been shown to correlate with anti T-cell immunity and efficacy of checkpoint inhibitor the

112 The contribution of host T-cell immunity and HLA class I alleles to the control o

113 ve the current understanding of HIV-specific T-cell immunity and identify cellular immune responses a

114 ng phase augmented DC vaccine-induced CD8(+) T-cell immunity and improved antitumor efficacy, suggest

115 hich is a prerequisite for successful CD8(+) T-cell immunity and protective vaccination, can only be

116 Here, CD8+ T-cell immunity and response to reinfection were assesse

117 iraemia, which leads to the establishment of T-cell immunity and resultant long-term infection contro

118 inib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of PD-1 blockad

119 B1 allele predicted resurgent virus-specific T-cell immunity and viral control at 3-mo postpartum (P

120 acute infectious agents induce strong CD8(+) T cell immunity, and are thought to therefore represent

121 Dendritic cells (DCs) are potent inducers of T cell immunity, and autologous DC vaccination holds pro

122 ml4 mAbs elicited combined CD4(+) and CD8(+) T cell immunity, and both T cells participated in resist

123 s contributes to the observed defects in CD8 T cell immunity, and therapeutic approaches designed to

124 er, these T cells support engraftment, early T-cell immunity, and mediate the graft-versus-tumor (GVT

125 rive Th17 polarization and influence mucosal T-cell immunity, and suggest that host pathways to handl

126 ections, and new vaccines that induce CD8(+) T cell immunity are currently needed.

127 or (TNFR)-associated factor (TRAF) family in T cell immunity are not well understood.

128 The study of T cell immunity at barrier surfaces has largely focused

129 94 HSCT recipients we evaluated CMV-specific T-cell immunity at baseline, 3, 6, 9, and 12 months afte

130 ease among those infected, but the impact of T-cell immunity at the population level is unknown.

131 aR signaling also has been shown to regulate T cell immunity, but its sites and mechanism of action i

132 have a negative impact on the development of T-cell immunity by using the murine lymphocytic choriome

133 T cell immunity can potentially eradicate malignant cell

134 Our results show that HIV-1-specific T-cell immunity can be detected in exposed but uninfecte

135 d to successful and sustained restoration of T-cell immunity correlated with virologic response and p

136 des from HPV-16 E6/E7 for which induction of T-cell immunity correlates with disease-free survival in

137 w evidence that stimulating effective CD8(+) T cell immunity could provide protection, and in this Pe

138 The fidelity of T cell immunity depends greatly on coupling T cell recep

139 /-) mice were deficient in generating CD8(+) T-cell immunity despite normal clonal expansion, likely

140 ent and thus distinct from the regulation of T cell immunity directed against many other viral pathog

141 Moreover, we advocate that tumor Ag-specific T cell immunity directed against self-proteins can be ex

142 T cell immunity directed against tumor-encoded amino aci

143 ding imply that exosomes function to promote T cell immunity during a bacterial infection and are an

144 ibutions of CD4 T cell help to antiviral CD8 T cell immunity during central nervous system (CNS) infe

145 fundamental role in the induction of CD8(+) T cell immunity during viral, intracellular bacterial, a

146 eal a mechanism by which S. Typhi may target T-cell immunity during establishment of typhoid.

147 this study, we analyzed the role of IAPs in T-cell immunity during lymphocytic choriomeningitis viru

148 Thus, maternal CD4(+) T-cell immunity during primary rhCMV infection is import

149 tant role of regulatory NK cells in limiting T-cell immunity during virus infection.

150 nocytogenes (which induces CD4(+) and CD8(+) T-cell immunity) engineered to express Kras(G12D) (LM-Kr

151 denoviral vectored vaccines fails to restore T-cell immunity except where there is genetic mismatch b

152 incident with development of strain-specific T-cell immunity followed by emergence of cross-reactive

153 le test to identify recovery of CMV-specific T-cell immunity following hematopoietic stem cell transp

154 Thus, CD8(+) T cell immunity generated during primary DENV infection

155 141(+) DCs in determining the type of CD8(+) T cell immunity generated to live-attenuated influenza v

156 Restoration of antigen-specific T cell immunity has the potential to clear persistent vi

157 T-cell immunity has been linked to the exceptional outco

158 bodies (mAbs) able to reinvigorate antitumor T-cell immunity have heralded a paradigm shift in cancer

159 should be targeted for optimal activation of T cell immunity, however, remains unknown.

160 current helminth infection potently inhibits T cell immunity; however, whether helminthes prevent T c

161 We prospectively analyzed antigen-specific B/T-cell immunity, immune composition of the tumor microen

162 While T cell immunity in brucellosis has been extensively stud

163 of these DC subsets to boost tumor-reactive T cell immunity in cancer patients.

164 producing subset of B cells able to regulate T cell immunity in CHB.

165 ptor (TCR) gene therapy can reconstitute CD8 T cell immunity in chronic patients.

166 ch there has been debate about centrality of T cell immunity in defense, these observations support a

167 d understanding the correlates of protective T cell immunity in HIV infection, the optimal approach t

168 e HLA class II alleles and then assessed CD4 T cell immunity in HLA class II transgenic mice and in s

169 of therapeutic type 1 antigen-specific CD8+ T cell immunity in humans with cancer.

170 ria, due to their ability to potently induce T cell immunity in humans.

171 have potential as new tools to characterize T cell immunity in influenza infection, and may serve as

172 Notably, a profound inhibition of secondary T cell immunity in LCMV-immune CD80/86-deficient mice em

173 itic cells (DCs) prime and orchestrate naive T cell immunity in lymphoid organs, but recent data also

174 A class II heterodimers and stimulate strong T cell immunity in mice and humans.

175 define antigenic epitopes determining CD8(+) T cell immunity in murine models of ZIKV infection.

176 led to the use of high-dose IL-2 to enhance T cell immunity in patients with AIDS or cancer.

177 display diminished capacity for controlling T cell immunity in prostate inflammation and cancer mode

178 ontributing factor leading to diminished CD8 T cell immunity in septic hosts.

179 tion can induce protective antifungal CD8(+) T cell immunity in the absence of CD4(+) T cells.

180 s for vaccines and/or therapies that require T cell immunity in the lung.

181 r (TSLPR), yet a direct role for TSLP in CD8 T cell immunity in the mucosa has not been described.

182 ion of TSLP levels may promote long-term CD8 T cell immunity in the mucosa when other prosurvival sig

183 Instead, its effect on T cell immunity in vivo may involve CD11b(+)F4/80(+) or

184 evaluated peripheral blood and lung mucosal T-cell immunity in 14 HIV(+)COPD(+), 13 HIV(+)COPD(-), a

185 However, little is known about KSHV-specific T-cell immunity in healthy donors and immune control of

186 ated signaling pathways in protective CD8(+) T-cell immunity in human subjects is unknown.

187 is therefore a novel functional component of T-cell immunity in latent TB and potential correlate of

188 nfections support the clinical importance of T-cell immunity in mediating protective antiviral effect

189 results suggest that IL-10 suppresses CD4(+) T-cell immunity in nonvaccinated mice during Coccidioide

190 This investigation of virus-specific T-cell immunity in patients with HDV infection, the larg

191 animals, indicating a minimal role for CD4+ T-cell immunity in rVSV-mediated protection.

192 eneous family of myeloid cells that suppress T-cell immunity in tumor-bearing hosts.

193 We measured influenza-specific CD4(+) T-cell immunity in unimmunized HIV-infected Malawian adu

194 eptor and the cytokine IL-2, but its role in T-cell immunity in vivo has not been explored.

195 o be of significant importance in regulating T-cell immunity in vivo.

196 odeficiencies are marked by inborn errors of T-cell immunity in which the T cells that are present ar

197 addition, NK cell depletion caused enhanced T-cell immunity in WT mice, which led to rapid virus con

198 tegies, the therapeutic goal is to re-ignite T-cell immunity, in order to eradicate tumors.

199 ere we discuss new approaches to probe human T cell immunity, including novel sampling, that indicate

200 One possibility is that T cell immunity incorporates an extremely high level of

201 Identification of positive regulators of T-cell immunity induced during autoimmune diseases is cr

202 the efficient induction of stable antiviral T cell immunity irrespective of the nature of the antige

203 Reconstitution of T cell immunity is absolutely critical for the effective

204 Induction of proinflammatory T cell immunity is augmented by innate dendritic cell (D

205 articular, IFN-gamma-polarized cytotoxic CD8 T cell immunity is considered optimal for protective imm

206 a better understanding of how protective CD8 T cell immunity is generated against Yersinia and other

207 e minimal thresholds for effective antiviral T cell immunity is important for clinical decisions in i

208 ection against reinfection and that adaptive T cell immunity is important for viral clearance.

209 eatment for malaria and other diseases where T cell immunity is ineffective or short-lived due to PD-

210 T cell immunity is often defined in terms of memory lymp

211 ivery of IL-1beta to determine that adaptive T cell immunity is required for airway remodeling becaus

212 of IFN-gamma in tuberculosis (TB), and CD4+ T cell immunity is the main target of current TB vaccine

213 T cell immunity is vital for the control of KSHV infecti

214 T-cell immunity is critical for control of CMV infection

215 istocompatibility complex class I-restricted T-cell immunity is essential to control infection with c

216 T-cell immunity is important for controlling Kaposi sarc

217 feration, suggesting that Arg1 regulation of T-cell immunity is involved in disease control.

218 An important question is whether T-cell immunity is sufficiently strong to drive influenz

219 Thus, eliciting robust CD8 T-cell immunity is the basis for many vaccines under dev

220 Adaptive CD8 T-cell immunity is the principal arm of the cellular all

221 c cell antigen presentation, but its role in T-cell immunity is unknown.

222 A characterization of RSV-specific T-cell immunity is warranted.

223 e importance of the immune adaptor SLP-76 in T-cell immunity, it has been unclear whether SLP-76 dire

224 mokine pathway is critical in shaping CD8(+) T cell immunity, locally within latently infected tissue

225 s, but it is unknown whether disturbances to T cell immunity may render these patients vulnerable to

226 immunogenic cell death, which could trigger T-cell immunity mediated by high-mobility group box 1 pr

227 T-cell immunity might be an essential component of safe,

228 enhanced dengue infections suggest that poor T-cell immunity might have contributed to protection fai

229 n of whether preexisting dengue virus (DENV) T cell immunity modulates these responses.

230 NV cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of gr

231 ts, we evaluated the contributions to CD8(+) T cell immunity of CD40 expressed on host tissues includ

232 ime a dual impact of host adaptive antitumor T-cell immunity on the clinical effectiveness of rapalog

233 have generally focused on either stimulating T cell immunity or driving antibody-directed effector fu

234 duction, pDCs can also process Ag and induce T cell immunity or tolerance.

235 We assessed whether vaccine-induced T-cell immunity, or expression of certain HLA alleles, i

236 nical observations suggest that VZV-specific T cell immunity plays a more critical role than humoral

237 ng Ab-mediated protection, the role that CD8 T cell immunity plays in overall VLP-mediated protection

238 his study, we sought to investigate the role T cell immunity plays in recognizing and controlling gen

239 ew the evidence of IL-33 to drive protective T cell immunity plus its potential use as an adjuvant in

240 Naturally occurring cross-protective T-cell immunity protects against symptomatic PCR-confirm

241 EPO-R signaling on T cells to inhibition of T-cell immunity, providing one mechanism that could expl

242 not lead to improved Ag presentation and CD8 T cell immunity; rather, it recruited FcgammaR-bearing i

243 d if this observed immunoparalysis of CD8(+) T cell immunity recovers, and the long-term consequences

244 processes involved in generation of durable T-cell immunity remain undefined.

245 T-cell immunity requires extremely rapid clonal prolifer

246 However, current LAIVs exert limited T cell immunity restricted to the vaccine strains.

247 Absent T-cell immunity resulting in life-threatening infections

248 Mouse studies of T cell immunity show that, in response to infection, T c

249 of B cells in TB vaccine-induced protective T cell immunity still remains unknown.

250 ent yet CD80/86-independent secondary CD8(+) T cell immunity suggests the existence of a CD28 ligand

251 e parameters of M. tuberculosis-specific CD4 T cell immunity that are impaired in HIV-infected indivi

252 s (LAIVs) have the potential to generate CD8 T cell immunity that may limit the virulence of an antig

253 related with high antibody titers yet CD4(+) T cell immunity that was significantly less potent than

254 ive functionality of TNFRSF4 and TNFRSF25 in T cell immunity, the activity of TNFRSF4 and TNFRS25 ago

255 te the importance of the co-receptor PD-1 in T cell immunity, the upstream signaling pathway that reg

256 Cs) might serve as targets for modulation of T-cell immunity, the particular role of DCs in immunity

257 ed mice with rLm/iglC significantly enhanced T cell immunity; their splenic T cells secreted signific

258 recruitment of mast cells and activation of T cell immunity through C3a are important for parasite c

259 Csf-2 is important in vaccine-induced CD8(+) T cell immunity through the regulation of nonlymphoid ti

260 fense, these observations support a role for T cell immunity to AhpC in disease protection.

261 6 of 7 treated patients developed sustained T cell immunity to all 3 melanoma gp100 antigen-derived

262 man neonates have reduced and delayed CD4(+) T cell immunity to certain pathogens, but the mechanisms

263 irus (CMV) persists in most humans, requires T cell immunity to control, yet tissue immune responses

264 T cell immunity to GroEL (BPSL2697) was specifically imp

265 epitope recognition by CD8(+)T cells, CD4(+)T cell immunity to KSHV may be important for maintaining

266 eceptor 3 (CXCR3) chemokine pathway promotes T cell immunity to many viral pathogens, but its importa

267 le for p110delta signaling in in vivo CD8(+) T cell immunity to microbial pathogens.

268 Survival was associated with enhanced T cell immunity to nine of fifteen immunodominant antige

269 oost mucosal vaccine for induction of CD8(+) T cell immunity to protect the female genital tract from

270 endogenous NK cell and tumor Ag-specific CD8 T cell immunity to provide a marked reduction in tumor b

271 iral pathogens, but its importance in CD8(+) T cell immunity to recurrent herpes has been poorly eluc

272 sistance may provide insight into protective T cell immunity to TB.

273 g allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including mesothelin

274 hese data indicate that protective antiviral T-cell immunity to CMV is generated by direct presentati

275 Studies of T-cell immunity to human cytomegalovirus (CMV) primarily

276 cations but the nature of naturally-acquired T-cell immunity to influenza virus in an African setting

277 erculosis infection, and in the evolution of T-cell immunity to M. tuberculosis in response to tuberc

278 he responder animal had a history of broader T-cell immunity to multiple HCV proteins than the two ch

279 n presentation, leading to the paradigm that T-cell immunity to these pathogens necessitates cross-pr

280 enhances the human NoV-specific mucosal and T cell immunities triggered by a VSV-based human NoV vac

281 tion; and (iv) inhibiting antitumor adaptive T cell immunity via the programmed death-1 (PD-1)-progra

282 as associated with more pronounced antitumor T-cell immunity via induction of IL17 and IFNgamma-produ

283 omain-containing molecule 4 (Tim4) regulates T-cell immunity via phagocytosis of both apoptotic (high

284 Here, patterns of T cell immunity, virus replication, and hepatocellular i

285 pothesis that impaired human neonatal CD4(+) T cell immunity was due to reduced signaling by naive CD

286 The LSEC-mediated CD8(+) T cell immunity was initiated by soluble mediators, one

287 ofound negative effect of IAP antagonists on T-cell immunity was partially linked to tumor necrosis f

288 genetic diagnosis nor basic measurements of T-cell immunity were good predictors of disease evolutio

289 be successfully sensitized to host antitumor T cell immunity when appropriately selected immunogenic

290 dendritic cells (DCs) is required to induce T cell immunity, whereas immature DCs can induce immune

291 ed to induce potent and durable local CD8(+) T cell immunity, which is crucial for protection against

292 undant activities of TNFRSF4 and TNFRSF25 in T cell immunity, which may guide the application of rece

293 converge on NFATc1 with opposing effects on T cell immunity, which may underlie the beneficial effec

294 in a lack of activation of antigen-specific T-cell immunity, which plays an important role in protec

295 um of which is necessary for preservation of T cell immunity while suppressing tissue damage.

296 atic CD4(+) T-cell compartment that suppress T-cell immunity while concomitantly promoting aberrant I

297 ovide criteria for optimizing protective CD8 T cell immunity with rAd vaccines.

298 itioning regulates the extent and quality of T cell immunity, with important implications for vaccine

299 etic cell transplantation is how to transfer T-cell immunity without causing graft-versus-host diseas

300 This may cause a relevant reduction in T-cell immunity, yielding a lowered risk for acute rejec